Comparison / Level D vs Level C

Pinealon vs Semax

Research Verdict

Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.

Quick Answers

Which is better, Pinealon or Semax?

Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.

What is the key difference between Pinealon and Semax?

Semax is an ACTH(4-7) analog with BDNF-mediated neuroprotection validated across multiple studies; pinealon is a Khavinson tripeptide with claimed neuroprotective effects that lack controlled evidence.

Evidence Comparison

Semax: multicenter RCT in ischemic stroke (Lebedeva 2008, n=60), approved in Russia and Ukraine. Pinealon: single-group studies from the Khavinson lab only, no controlled trials, no independent replication. Semax is categorically stronger.

Evidence Context Favoring Pinealon

No evidence-based scenario favors pinealon over semax for neuroprotection or cognitive enhancement.

Evidence Context Favoring Semax

Any neuroprotective or cognitive enhancement research - semax has the multicenter RCT evidence and regulatory approval.

Side-by-Side Snapshot

Evidence gradePinealon: Level D
Semax: Level C
Research statusPinealon: Early Research
Semax: Approved Outside US
Primary categoryPinealon: Cognitive & Nootropic
Semax: Cognitive & Nootropic
Cited studiesPinealon: 2
Semax: 2

Read Next